Therapy of recurrent and refractory multiple Myeloma Isatuximab improves progression-free Survival

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：397 / 397
页数：1
相关论文
共 50 条
  • [1] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
  • [2] Combination Therapy with Isatuximab in relapsed multiple Myeloma Superior progression-free Survival and clinically meaningful Depth of Response
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [3] MPT improves progression-free survival in elderly patients with multiple myeloma
    不详
    [J]. Nature Clinical Practice Oncology, 2009, 6 (1): : 4 - 4
  • [4] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [5] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [6] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    [J]. Leukemia, 2011, 25 : 1620 - 1626
  • [7] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    [J]. LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [8] Second-line Therapy for Patients with multiple Myeloma - almost 3 Years progression-free Survival with Combination of Isatuximab, Proteasome Inhibitor and Dexamethasone
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [9] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
    Avet-Loiseau, Herve
    Fonseca, Rafael
    Siegel, David
    Dimopoulos, Meletios A.
    Spicka, Ivan
    Masszi, Tamas
    Hajek, Roman
    Rosinol, Laura
    Goranova-Marinova, Vesselina
    Mihaylov, Georgi
    Maisnar, Vladimir
    Mateos, Maria-Victoria
    Wang, Michael
    Niesvizky, Ruben
    Oriol, Albert
    Jakubowiak, Andrzej
    Minarik, Jiri
    Palumbo, Antonio
    Bensinger, William
    Kukreti, Vishal
    Ben-Yehuda, Dina
    Stewart, A. Keith
    Obreja, Mihaela
    Moreau, Philippe
    [J]. BLOOD, 2016, 128 (09) : 1174 - 1180
  • [10] Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients.
    Berenson, J
    Crowley, J
    Barlogie, B
    Salmon, S
    [J]. BLOOD, 1998, 92 (10) : 318A - 318A
12345